Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) issued its earnings results on Thursday. The company reported ($0.21) EPS for the quarter, Zacks reports.
Eupraxia Pharmaceuticals Trading Down 2.7 %
Shares of EPRX traded down $0.11 on Thursday, reaching $3.91. The company’s stock had a trading volume of 5,147 shares, compared to its average volume of 16,544. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $4.48. The stock has a market capitalization of $139.38 million and a PE ratio of -5.43. The firm has a fifty day moving average of $3.46 and a 200-day moving average of $3.09.
Wall Street Analysts Forecast Growth
Separately, Craig Hallum initiated coverage on Eupraxia Pharmaceuticals in a research report on Friday, February 21st. They set a “buy” rating and a $12.00 target price on the stock.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Read More
- Five stocks we like better than Eupraxia Pharmaceuticals
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- How to Invest in Insurance Companies: A Guide
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
